Federal Register / Vol. 70, No. 165 / Friday, August 26, 2005 / Notices 50377

TABLE 1.

Sponsor NADA Number, Product (Drug) 

21 CFR Section Affected, 

(Sponsor Drug Labeler 

Code) 

Abbott Laboratories, North Chicago, IL 

60064

NADA 99–568, FURANACE Caps (nifurpirinol) 529.1526 (000074) 

Biocraft Laboratories, Inc., 92 Route 46, 

Elmwood Park, NJ 07407

NADA 140–889, DERM–OTIC Ointment (neomycin sulfate, nystatin, thiostrepton, triamcinolone acetonide) 524.1600a (000332) 

First Priority, Inc., 1585 Todd Farm Dr., 

Elgin, IL 60123

NADA 48–646, THERAZONE Injection (phenylbutazone) 522.1720 (058829) 

Happy Jack, Inc., Snow Hill, NC 28580 NADA 121–556, Selenium Sulfide Suspension (selenium disulfide) 524.2101 (023851) 

NADA 121–723, Nitrofurazone Dressing 524.1580b (023851) 

NADA 125–137, FILARICIDE Capsules (diethylcarbamazine citrate) 520.622d (023851) 

IMPAX Laboratories, Inc., 30831 Huntwood 

Ave., Hayward, CA 94544

NADA 92–151, N-Butyl Chloride Canine Worming Caps 520.260 (000115) 

NADA 65–065, Tetracycline HCl Caps 520.2345a (000115) 

NADA 138–900, Dichlorophene/Toluene 520.580 (000115) 

Jorgensen Laboratories, Inc., 1450 North 

Van Buren Ave., Loveland, CO 80538

NADA 10–481, SUREJETS (salacylic acid) 529.2090 (048087) 

Pliva d.d., Ulica grada Vukovara 49, 10000 

Zagreb, Croatia 

ANADA, 200–232, GEOMYCIN 200 Injection (oxytetracycline) 522.1660a (011722) 

Purina Mills, Inc., P.O. Box 66812, St. Louis, 

MO 63166-6812

NADA 65–113 AUREO Sulfa Soluble Powder (chlortetracycline/

sulfamethazine) 

N/A (017800) 

Roche Vitamins, Inc., 45 Waterview Blvd., 

Parsippany, NJ 07054–1298

NADA 140–848, VETEEZE Injection (diazepam) 522.575 (063238) 

Teva Pharmaceuticals USA, 650 Cathill Rd., 

Sellersville, PA 18960

NADA 131–806, Furosemide Tablets 520.1010 (000093) 

Virbac AH, Inc., 3200 Meacham Blvd., Ft. 

Worth, TX 76137

NADA 10–886, Purina Liquid Wormer (piperazine citrate) N/A (051311) 

Wyeth Laboratories, Division of American 

Home Products Corp., P.O. Box 8299, 

Philadelphia, PA 19101

NADA 10–782, SPARINE Injection (promazine) 522.1962 (000008) 

NADA 55–008, BICILLIN Fortified (penicillin G benzathine and 

penicillin G procaine) 

522.1696a (000008) 

Therefore, under authority delegated 

to the Commissioner of Food and Drugs 

(21 CFR 5.10), redelegated to the Center 

for Veterinary Medicine (21 CFR 5.84), 

and in accordance with § 514.115 

Withdrawal of approval of applications

(21 CFR 514.115), notice is given that 

approval of NADAs 10–481, 10–782, 

10–886, 48–646, 55–008, 65–065, 65–

113, 99–568, 121–556, 121–723, 125–

137, 131–806, 138–900, 140–848, 140–

889, and ANADA 200–232, and all 

supplements and amendments thereto, 

is hereby withdrawn, effective 

September 6, 2005.

In a final rule published elsewhere in 

this issue of the Federal Register, FDA 

is amending the animal drug regulations 

to reflect the withdrawal of approval of 

these NADAs.

Dated: July 5, 2005.

Linda Tollefson,

Acting Director, Center for Veterinary 

Medicine.

[FR Doc. 05–16994 Filed 8–25–05; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Establishment 

Pursuant to the Federal Advisory 

Committee Act, as amended (5 U.S.C. 

Appendix 2), the Director, National 

Institutes of Health (NIH), announces 

the establishment of the National 

Commission on Digestive Diseases 

(Commission). 

This Commission shall conduct an 

overview of the state-of-the-science in 

the field of digestive diseases research 

and develop a long-range plan for 

digestive diseases research consistent 

with the research mission of NIH. The 

overall plan will focus on the goal of 

improving the health of the nation 

through digestive diseases research and 

will include specific objectives and 

goals and a recommended time line for 

their implementation. 

Recommendations shall be made to the 

Director, NIH and to Congress. 

The Commission shall be composed 

of 16 members appointed by the 

Director, NIH and 18 nonvoting ex 

officio members. Of the appointed 

members, who shall have a broad 

diversity of scientific and professional 

experience, 12 shall be knowledgeable 

about digestive diseases as members of 

academic or medical research and 

practice communities involved in 

digestive diseases research, including 

50378 Federal Register / Vol. 70, No. 165 / Friday, August 26, 2005 / Notices 

individuals in allied health specialties 

relevant to digestive diseases research. 

Four members shall be appointed who 

have close personal or family 

experience with digestive diseases or 

experience with patient-oriented 

organizations in digestive diseases. 

Unless renewed by appropriate action 

prior to its expiration, the Charter for 

the National Commission on Digestive 

Diseases will expire two years from the 

date of establishment.

Dated: August 16, 2005. 

Elias A. Zerhouni, 

Director, National Institutes of Health.

[FR Doc. 05–17012 Filed 8–25–05; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Advisory Committee to the Director, 

NIH. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: Advisory Committee 

to the Director, NIH. 

Date: September 6, 2005. 

Time: 11 a.m. to 12 p.m. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Room 5B64, 

Bethesda, MD 20892. 

Agenda: To review and evaluate grant 

applications (Telephone Conference Call). 

Contact Person: Shelly Pollard, ACD 

Coordinator, National Institutes of Health, 

9000 Rockville Pike, Building 31, Room 

5B64, Bethesda, MD 20892, 301–496–0959. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person.

Dated: August 19, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 05–17016 Filed 8–25–05; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

National Cancer Advisory Board. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4), and 552b(c)(6), as amended. 

The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Advisory Board. 

Open: September 20, 2005, 8 a.m. to 4:15 

p.m. 

Agenda: Program reports and 

presentations; Business of the Board. 

Place: National Cancer Institute, 9000 

Rockville Pike, Building 31, C Wing, 6th 

Floor, Conference Room 10, Bethesda, MD 

20892. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147.

Name of Committee: National Cancer 

Advisory Board. 

Closed: September 20, 2005, 4:15 p.m. to 

Adjournment. 

Agenda: Review of grant applications. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147.

Name of Committee: National Cancer 

Advisory Board. 

Open: September 21, 2005, 8 a.m. to 12 

p.m. 

Agenda: Program reports and 

presentations; Business of the Board. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147.

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s Home page: 

deainfo.nci.nih.gov/advisory/ncab.htm,

where an agenda and any additional 

information for the meeting will be posted 

when available.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS.)

Dated: August 18, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 05–17011 Filed 8–25–05; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

properly such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel Basic Science. 

Date: October 17–18, 2005. 

Time: 8 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications.